» Articles » PMID: 29270239

Targeted Bisulfite Sequencing Identified a Panel of DNA Methylation-based Biomarkers for Esophageal Squamous Cell Carcinoma (ESCC)

Overview
Publisher Biomed Central
Specialty Genetics
Date 2017 Dec 23
PMID 29270239
Citations 43
Authors
Affiliations
Soon will be listed here.
Abstract

Background: DNA methylation has been implicated as a promising biomarker for precise cancer diagnosis. However, limited DNA methylation-based biomarkers have been described in esophageal squamous cell carcinoma (ESCC).

Methods: A high-throughput DNA methylation dataset (100 samples) of ESCC from The Cancer Genome Atlas (TCGA) project was analyzed and validated along with another independent dataset (12 samples) from the Gene Expression Omnibus (GEO) database. The methylation status of peripheral blood mononuclear cells and peripheral blood leukocytes from healthy controls was also utilized for biomarker selection. The candidate CpG sites as well as their adjacent regions were further validated in 94 pairs of ESCC tumor and adjacent normal tissues from the Chinese Han population using the targeted bisulfite sequencing method. Logistic regression and several machine learning methods were applied for evaluation of the diagnostic ability of our panel.

Results: In the discovery stage, five hyper-methylated CpG sites were selected as candidate biomarkers for further analysis as shown below: cg15830431,  = 2.20 × 10; cg19396867,  = 3.60 × 10; cg20655070,  = 3.60 × 10; cg26671652,  = 5.77 × 10; and cg27062795,  = 3.60 × 10. In the validation stage, the methylation status of both the five CpG sites and their adjacent genomic regions were tested. The diagnostic model based on the combination of these five genomic regions yielded a robust performance (sensitivity = 0.75, specificity = 0.88, AUC = 0.85). Eight statistical models along with five-fold cross-validation were further applied, in which the SVM model reached the best accuracy in both training and test dataset (accuracy = 0.82 and 0.80, respectively). In addition, subgroup analyses revealed a significant difference in diagnostic performance between the alcohol use and non-alcohol use subgroups.

Conclusions: Methylation profiles of the five genomic regions covering cg15830431 (), cg19396867, cg20655070, cg26671652 (), and cg27062795 () can be used for effective methylation-based testing for ESCC diagnosis.

Citing Articles

DNA methylation markers in esophageal cancer.

Xu Y, Wang Z, Pei B, Wang J, Xue Y, Zhao G Front Genet. 2024; 15:1354195.

PMID: 38774285 PMC: 11106492. DOI: 10.3389/fgene.2024.1354195.


Low expression of miR-182 caused by DNA hypermethylation accelerates acute lymphocyte leukemia development by targeting PBX3 and BCL2: miR-182 promoter methylation is a predictive marker for hypomethylation agents + BCL2 inhibitor venetoclax.

Li D, Yuan Y, Meng C, Lin Z, Zhao M, Shi L Clin Epigenetics. 2024; 16(1):48.

PMID: 38528641 PMC: 10964616. DOI: 10.1186/s13148-024-01658-2.


Hippo cooperates with p53 to maintain foregut homeostasis and suppress the malignant transformation of foregut basal progenitor cells.

Jiang Y, Huang H, Liu J, Luo D, Mu R, Yuan J Proc Natl Acad Sci U S A. 2024; 121(10):e2320559121.

PMID: 38408237 PMC: 10927585. DOI: 10.1073/pnas.2320559121.


Genome-wide discovery of circulating cell-free DNA methylation biomarkers for colorectal cancer detection.

Fang Q, Yuan Z, Hu H, Zhang W, Wang G, Wang X Clin Epigenetics. 2023; 15(1):119.

PMID: 37501075 PMC: 10375686. DOI: 10.1186/s13148-023-01518-5.


Circulating DNA methylation level of CXCR5 correlates with inflammation in patients with rheumatoid arthritis.

Shi Y, Chang C, Xu L, Jiang P, Wei K, Zhao J Immun Inflamm Dis. 2023; 11(6):e902.

PMID: 37382265 PMC: 10288483. DOI: 10.1002/iid3.902.


References
1.
Zhou D, Conrad C, Xia F, Park J, Payer B, Yin Y . Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. Cancer Cell. 2009; 16(5):425-38. PMC: 3023165. DOI: 10.1016/j.ccr.2009.09.026. View

2.
Takeshita N, Hoshino I, Mori M, Akutsu Y, Hanari N, Yoneyama Y . Serum microRNA expression profile: miR-1246 as a novel diagnostic and prognostic biomarker for oesophageal squamous cell carcinoma. Br J Cancer. 2013; 108(3):644-52. PMC: 3593570. DOI: 10.1038/bjc.2013.8. View

3.
Schwartzman O, Tanay A . Single-cell epigenomics: techniques and emerging applications. Nat Rev Genet. 2015; 16(12):716-26. DOI: 10.1038/nrg3980. View

4.
Yang X, Gao L, Zhang S . Comparative pan-cancer DNA methylation analysis reveals cancer common and specific patterns. Brief Bioinform. 2016; 18(5):761-773. DOI: 10.1093/bib/bbw063. View

5.
Hirajima S, Komatsu S, Ichikawa D, Takeshita H, Konishi H, Shiozaki A . Clinical impact of circulating miR-18a in plasma of patients with oesophageal squamous cell carcinoma. Br J Cancer. 2013; 108(9):1822-9. PMC: 3658511. DOI: 10.1038/bjc.2013.148. View